Welcome to our dedicated page for Oscar Health SEC filings (Ticker: OSCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oscar Health, Inc. (NYSE: OSCR) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. Oscar identifies itself in these filings as a healthcare technology company whose Class A common stock trades on the New York Stock Exchange under the symbol OSCR. Through its reports, investors can review how the company structures its health insurance operations, technology initiatives, and capital markets activities.
Oscar’s annual reports on Form 10-K and quarterly reports on Form 10-Q provide overviews of its Individual & Family health plans, health technology solutions under the +Oscar brand, risk factors, and detailed financial statements. These core filings typically include information on revenues, medical costs, selling, general, and administrative expenses, membership metrics, and key non-GAAP measures such as Adjusted EBITDA, along with management’s discussion of business drivers.
The company’s current reports on Form 8-K offer more targeted updates. Recent 8-K filings describe quarterly financial results, reaffirmed guidance, and capital structure actions such as the issuance of 2.25% Convertible Senior Subordinated Notes due 2030, related capped call transactions, and an exchange agreement involving 7.25% Convertible Senior Notes due 2031. Other 8-Ks detail amendments to investment agreements, the planned termination of a revolving credit facility in connection with a notes offering, and changes to executive employment agreements and compensation structures.
Investors can also use this page to access information on convertible debt terms, events of default, subordination provisions, and potential share dilution from note conversion, all of which are described in Oscar’s indentures and related exhibits. Stock Titan’s AI summaries help explain the implications of these filings, highlight key sections of lengthy documents, and surface important items such as changes in guidance, financing transactions, and governance-related disclosures. This makes it easier to understand how Oscar’s regulatory filings relate to its health insurance operations, technology platform, and long-term financial strategy.
Oscar Health (OSCR) reported a director equity transaction. A director received 1,034 deferred stock units on October 9, 2025 at $20.54 per unit under the company’s Amended and Restated Deferred Compensation Plan for Directors, electing DSUs in lieu of a cash retainer. Each DSU represents the right to receive one share of Class A common stock and is 100% vested on the grant date. DSUs will be settled for cash or shares, at the company’s discretion, within 45 days of the earliest of termination of service, a change in control, death, or disability. Following this grant, the reporting person held 4,136 derivative securities directly.
Oscar Health (OSCR) Form 4: A director acquired 2,555 deferred stock units on October 9, 2025, reported with transaction code A. The price of $20.54 reflects the Class A common stock closing price used to calculate the number of units under the company’s director deferred compensation plan. Each unit represents a right to receive one share of Class A common stock. Following this grant, the director beneficially owned 63,142 derivative securities, held directly. The units are 100% vested on the grant date and will be settled in cash or shares at the company’s discretion upon specified triggering events.
Oscar Health insider filings show option exercise and share sale by Mario Schlosser. Mr. Schlosser exercised 555,165 vested stock options with a $6.36 exercise price on 09/22/2025, creating the right to 555,165 Class A shares. Concurrently he converted and sold 395,000 Class A shares in multiple transactions at a weighted average price of $18.43 to cover the exercise cost and tax withholding, leaving him with 501,148 Class A shares beneficially owned. Certain remaining shares are held indirectly in family dynasty trusts over which he disclaims beneficial ownership except for any pecuniary interest.
Oscar Health, Inc. (OSCR) submitted a Form 144 notice reporting a proposed sale of 395,000 common shares through Morgan Stanley Smith Barney LLC on the NYSE with an approximate aggregate market value of $7,280,995.50. The filing shows the shares were acquired and will be sold on 09/22/2025 via exercise of options under a registered plan and payment was in cash. The filer reports 223,044,000 shares outstanding for the issuer and indicates no other securities were sold in the past three months. The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.
Oscar Health, Inc. filed an 8-K reporting execution of an Indenture dated September 18, 2025 between the company and U.S. Bank Trust Company, National Association as trustee. The filing includes the form of certificate for 2.25% Convertible Senior Subordinated Notes due 2030 (Exhibit A to Exhibit 4.1) and a form of Capped Call Confirmation. The submission also contains the cover page interactive data file embedded in the inline XBRL document. The filing is signed by R. Scott Blackley, Chief Financial Officer.
Oscar Health, Inc. filed an 8-K reporting that it has given notice of its intent to terminate the revolving credit facility that is part of its senior secured credit agreement with Wells Fargo Bank, N.A. and other lenders; the termination is contingent on the closing of an offering and will occur concurrently with that closing. The company disclosed an offering of notes to qualified institutional buyers under Rule 144A, and attached a press release as Exhibit 99.1. The report is signed by R. Scott Blackley, Chief Financial Officer and dated September 16, 2025.
Oscar Health, Inc. disclosed an amendment to its January 27, 2022 Investment Agreement with Dragoneer-affiliated funds to permit an offering of securities. The filing states the company expects to terminate its revolving credit facility concurrently with the closing of the offering; that termination is contingent on the offering closing. The offering is described as a Rule 144A placement to qualified institutional buyers. A press release dated September 15, 2025 is attached as Exhibit 99.1 and the report is signed by Chief Financial Officer R. Scott Blackley.
Victoria Baltrus, identified as the issuer's Chief Accounting Officer, reported a transaction on 09/02/2025 involving Class A common stock of Oscar Health, Inc. (OSCR). The filing shows a Code F disposition on 09/02/2025 where 6,266 shares were withheld by the issuer to satisfy tax withholding at a reported price of $16.66 per share. After the transaction, Baltrus is reported to beneficially own 207,599 shares, which the filing states includes shares to be issued upon RSU vesting. The form was signed by an attorney-in-fact on 09/04/2025.
Oscar Health insider reported a disposition of Class A common stock by Richard Scott Blackley, the company's Chief Financial Officer and director. On 09/02/2025 the filing shows 28,166 shares of Class A common stock were disposed of under transaction code F at a price of $16.66 per share. After the reported transaction, Mr. Blackley beneficially owned 1,376,169 shares. The filing explains 28,166 shares were withheld by the issuer to satisfy tax withholding on vested restricted stock units and that the post-transaction holdings include shares to be issued upon RSU vesting. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Janet Liang, President of Oscar Insurance and a reporting person for Oscar Health, Inc. (OSCR), reported changes in her beneficial ownership on a Form 4. On 09/02/2025 she had 7,303 shares of Class A common stock disposed under transaction code F at a price of $16.66 per share; the filing explains these shares were withheld by the issuer to satisfy tax withholding arising from the vesting of restricted stock units (RSUs). After the reported transaction(s), Ms. Liang beneficially owns 179,865 shares of Class A common stock, which includes shares to be issued in connection with the vesting of one or more RSUs. The Form 4 is signed by an attorney-in-fact on 09/04/2025.